Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å lære om studiemedisinen PF-08634404 som enkelbehandling og kombinasjonsbehandling hos voksne deltakere med en leverkreft kalt hepatocellulært karcinom, som er for avansert til å fjernes ved kirurgi og kan ha spredt seg til andre deler av kroppen.

6. oktober 2026 oppdatert av: Pfizer

EN INTERVENSJONELL ÅPEN ETIKETTFASE 1B/2-STUDIE FOR Å VURDERE SIKKERHET, FARMAKOKINETIKK OG FORELØPIG EFFEKT AV PF-08634404 SOM MONOTERAPI OG KOMBINASJONSTERAPI HOS VOKSNE DELTAKERE MED UOPERERBAR LOKALT AVANSERT ELLER METASTATISK HEPATOCELLULÆRT KARSINOM

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have locally advanced or metastatic HCC.
  • Is not a candidate for complete surgical or loco-regional therapies.
  • Have not received any whole-body treatment for HCC.

Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

138

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Irvine, California, Forente stater, 92612
        • Rekruttering
        • Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Irvine, California, Forente stater, 92612
        • Rekruttering
        • UCI Health - Irvine Infusion Pharmacy ACC
      • Irvine, California, Forente stater, 92612
        • Rekruttering
        • UCI Health - Irvine
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • USC/Norris Comprehensive Cancer Center
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • Keck Hospital of USC
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • USC/Norris Comprehensive Cancer Center / Investigational Drug Services
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • Los Angeles General Medical Center
      • Los Angeles, California, Forente stater, 90025
        • Rekruttering
        • START Los Angeles, LLC
      • Los Angeles, California, Forente stater, 90067
        • Rekruttering
        • LACN Century City
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • UC Irvine Health - Chao Family Comprehensive Cancer Center
      • Pasadena, California, Forente stater, 91105
        • Rekruttering
        • Keck Medical Center of USC Pasadena
    • Florida
      • Land O' Lakes, Florida, Forente stater, 34638
        • Rekruttering
        • Moffitt Cancer Center at Speros
      • Ruskin, Florida, Forente stater, 33570
        • Rekruttering
        • Moffitt Cancer Center at SouthShore
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center - McKinley Campus
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt McKinley Hospital
      • Tampa, Florida, Forente stater, 33607
        • Rekruttering
        • Moffitt Cancer Center - International Plaza
      • Wesley Chapel, Florida, Forente stater, 33544
        • Rekruttering
        • Moffitt Cancer Center at Wesley Chapel
    • Illinois
      • Shiloh, Illinois, Forente stater, 62269
        • Rekruttering
        • Siteman Cancer Center - Shiloh
      • Shiloh, Illinois, Forente stater, 62269
        • Rekruttering
        • Memorial Hospital
    • Minnesota
      • Coon Rapids, Minnesota, Forente stater, 55433
        • Rekruttering
        • Allina Health Cancer Institute - Mercy Hospital
      • Minneapolis, Minnesota, Forente stater, 55407
        • Rekruttering
        • Allina Health Cancer Institute - Abbott Northwestern Hospital
      • Saint Paul, Minnesota, Forente stater, 55102
        • Rekruttering
        • Allina Health Cancer Institute - United Hospital
    • Missouri
      • City of Saint Peters, Missouri, Forente stater, 63376
        • Rekruttering
        • Siteman Cancer Center - St. Peters
      • Creve Coeur, Missouri, Forente stater, 63141
        • Rekruttering
        • Siteman Cancer Center - West County
      • Florissant, Missouri, Forente stater, 63031
        • Rekruttering
        • Siteman Cancer Center - North County
      • Kansas City, Missouri, Forente stater, 64111
        • Rekruttering
        • Saint Luke's Hospital of Kansas City
      • Kansas City, Missouri, Forente stater, 64111
        • Rekruttering
        • Saint Luke's Cancer Institute
      • St Louis, Missouri, Forente stater, 63108
        • Rekruttering
        • Siteman Cancer Center
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine - Siteman Cancer Center
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Forente stater, 63129
        • Rekruttering
        • Siteman Cancer Center - South County
    • Nevada
      • Reno, Nevada, Forente stater, 89502
        • Rekruttering
        • Renown Regional Medical Center
      • Reno, Nevada, Forente stater, 89502
        • Rekruttering
        • Renown Health Medical Oncology
      • Reno, Nevada, Forente stater, 89502
        • Rekruttering
        • Renown Office of Clinical Research
    • North Carolina
      • Cary, North Carolina, Forente stater, 27518
        • Rekruttering
        • Duke Cancer Center Cary
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke Cancer Center
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University - Main Hospital and Clinics
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke Cancer Center - Investigational Chemotherapy Service
      • Raleigh, North Carolina, Forente stater, 27609
        • Rekruttering
        • Duke Cancer Center Raleigh
    • Ohio
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Rekruttering
        • AHN Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Rekruttering
        • AHN Cancer Institute at Allegheny General Hospital
    • Washington
      • Seattle, Washington, Forente stater, 98101
        • Rekruttering
        • Virginia Mason Medical Center
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington Medical Center- Montlake
      • Fukuoka, Japan, 811-1395
        • Rekruttering
        • National Hospital Organization Kyushu Cancer Center
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Rekruttering
        • National Cancer Center Hospital East
    • Osaka
      • Sakai, Osaka, Japan, 590-0197
        • Rekruttering
        • Kindai University Hospital- Osaka Medical Campus
    • Tokyo
      • Chuo-ku, Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekruttering
        • Zhongshan Hospital,Fudan University
      • San Juan, Puerto Rico, 00909
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC
    • United States of America
      • Dorado, United States of America, Puerto Rico, 00646
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Dorado Office
      • Mayagüez, United States of America, Puerto Rico, 00680
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Mayaguez Office
      • Ponce, United States of America, Puerto Rico, 00730
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Ponce Office
      • Taichung, Taiwan, 407
        • Rekruttering
        • Taichung Veterans General Hospital
      • Tainan, Taiwan, 704
        • Rekruttering
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10002
        • Rekruttering
        • National Taiwan University Hospital
      • Taipei, Taiwan, 112
        • Rekruttering
        • Taipei Veterans General Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • 18 years of age or older at screening.
  • Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
  • Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
  • At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
  • Adequate hepatic, liver, and renal function
  • No prior systemic therapy for HCC.
  • ECOG performance status 0 or 1
  • Child-Pugh Class A

Key Exclusion Criteria:

  • Moderate or severe ascites.
  • History of hepatic encephalopathy.
  • Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
  • Clinically significant risk of hemorrhage or fistula.
  • Participants with any history of another malignancy within 3 years.
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
  • Clinically significant cardiovascular disease within 6 months prior to the first dose.
  • Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
  • History of severe bleeding tendency or coagulation dysfunction.
  • History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
  • Participants with acute, chronic or symptomatic infections.
  • Participants with history of immunodeficiency.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 1b

Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab.

Solution for infusion

Solution for infusion

Andre navn:
  • YERVOY
Eksperimentell: Phase 2

Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab.

Solution for infusion

Solution for infusion

Andre navn:
  • YERVOY

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Adverse Events
Tidsramme: Through end of study and up to approximately 24 months

Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Through end of study and up to approximately 24 months
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
Tidsramme: Through 90 days after the last dose of study intervention; Approximately 24 months

DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period.

Through 90 days after the last dose of study intervention; Approximately 24 months
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 24 months

ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator.

Approximately 24 months
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
Tidsramme: Approximately 24 months

The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2.

Approximately 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 24 months

ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator.

Approximately 24 months
Duration of Response (DOR) per RECIST 1.1 by investigator
Tidsramme: Approximately 24 months

DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 24 months
Progression Free Survival (PFS) per RECIST 1.1 by investigator
Tidsramme: Approximately 24 months

PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 24 months
Overall Survival (OS)
Tidsramme: Approximately 24 months

OS is defined as the time from the date of first dose to the date of death due to any cause.

Approximately 24 months
Number of Participants With Clinical Laboratory Abnormalities
Tidsramme: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Tidsramme: Up to 24 months

Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab.

Up to 24 months
Incidence of antidrug antibody against PF-08634404
Tidsramme: Up to 24 months

To evaluate immunogenicity of PF-08634404 in combination with ipilimumab.

Up to 24 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2025

Primær fullføring (Antatt)

18. oktober 2027

Studiet fullført (Antatt)

17. oktober 2028

Datoer for studieregistrering

Først innsendt

7. november 2025

Først innsendt som oppfylte QC-kriteriene

7. november 2025

Først lagt ut (Faktiske)

12. november 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere